---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-274405"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:17:33.053114+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# KalVista reports $13.7M Q3 net product revenue from EKTERLY launch; 937 patient start forms through Oct

## Summary
- Net product revenue of $13.7M for Q3 ended Sept 30, 2025, first full quarter of EKTERLY commercial launch.
- 937 patient start forms received and 423 unique prescribers activated through Oct 31, 2025.
- Cash and marketable securities of $309.2M; expects to fund through profitability.
- EKTERLY approved in EU, Switzerland, and Australia; Germany launch initiated Oct 2025.
- R&D expenses $12.0M (down from $18.7M); SG&A $46.5M (up from $24.8M) due to commercialization.

## SEC filing metadata
- accession: 0001193125-25-274405
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000119312525274405/0001193125-25-274405-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000119312525274405/d43801d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-274405
- JSON: https://secwatch.observer/filing/0001193125-25-274405.json
- Plain text: https://secwatch.observer/filing/0001193125-25-274405.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.